Page last updated: 2024-11-08

shikonin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

shikonin: a naphthazarin; has antineoplastic and angiogenesis inhibiting activities [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID479503
CHEBI ID81068
SCHEMBL ID33969
MeSH IDM0065857

Synonyms (64)

Synonym
1,4-naphthalenedione, 5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methyl-3-pentenyl]-
tokyo violet
shikonin
517-89-5
isoarnebin 4
5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methyl-pent-3-enyl]naphthalene-1,4-dione
c.i. 75535
nsc-252844
(+)-shikonin
1,4-naphthoquinone, 5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-, (+)-
1,4-naphthalenedione, 5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-, (r)-
nsc 252844
(+)-5,8-dihydroxy-2-(1-hydroxy-4-methyl-3-pentenyl)-1,4-naphthoquinone
brn 2058010
ccris 6492
C15906
BSPBIO_001270
shikonine
NCGC00163489-01
NCGC00163489-02
5,8-dihydroxy-2-((1r)-1-hydroxy-4-methyl-3-penten-1-yl)-1,4-naphthalenedione
(r)-(+)-shikonin
1,4-naphthalenedione, 5,8-dihydroxy-2-((1r)-1-hydroxy-4-methyl-3-pentenyl)-
HMS1990P11
HMS2089L09
5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methylpent-3-enyl]naphthalene-1,4-dione
chebi:81068 ,
C17412 ,
HMS1792P11
(r)-5,8-dihydroxy-2-(1-hydroxy-4-methylpent-3-en-1-yl)naphthalene-1,4-dione
3ik6592ubw ,
hsdb 8100
unii-3ik6592ubw
shikonin s
NCGC00163489-04
AKOS015900416
S8279
BP-30212
NEZONWMXZKDMKF-SNVBAGLBSA-N
CCG-208272
MLS006010149
smr002530673
5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methylpent-3-en-1-yl]-1,4-dihydronaphthalene-1,4-dione
SCHEMBL33969
J-502235
HY-N0822
CS-5906
(r)-shikonin
5,8-dihydroxy-2-((1r)-1-hydroxy-4-methylpent-3-enyl)naphthalene-1,4-dione
AC-26871
HMS3403P11
DTXSID30199653 ,
mfcd00075680
SR-05000001466-3
SR-05000001466-1
sr-05000001466
Q27155024
shikonin,(s)
AS-13554
5,8-dihydroxy-2-[(1r)-1-hydroxy-4-methyl-3-penten-1-yl]-1,4-naphthalenedione
AMY39404
c.i. 75535;isoarnebin 4
NCGC00163489-05
dtxcid90122144

Research Excerpts

Overview

Shikonin (SHI) is a natural naphthoquinone compound isolated from the Chinese herb Radix Arnebiae. The natural dye has proven its role as an anti-cancer, anti-inflammatory, and anti-gonadotrophic agent.

ExcerptReferenceRelevance
"Shikonin is a promising phytochemical for drug candidates. "( Shikonin, a naphthalene ingredient: Therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical researches.
Chen, L; Gong, T; Liu, M; Meng, X; Ming, T; Ren, S; Sun, Q; Xu, H; Yang, H; Zeng, S; Zhao, H, 2022
)
3.61
"Shikonin (SHI) is a natural naphthoquinone compound isolated from the Chinese herb Radix Arnebiae."( NGR-modified PEG-PLGA micelles containing Shikonin enhance targeting of dendritic cells for therapy of allergic rhinitis.
Liu, C; Qi, W; Qin, Y; Shi, L; Teng, Z; Xi, Y; Xia, M; Xu, F; Xu, R; Zhao, M, 2022
)
1.71
"Shikonin(SK) is a natural small molecule naphthoquinone compound, which has anti-cancer activity in various human malignant tumors. "( Shikonin induces apoptosis and autophagy via downregulation of pyrroline-5-carboxylate reductase1 in hepatocellular carcinoma cells.
Jiang, W; Shang, L; Wu, W; Zhang, J, 2022
)
3.61
"Shikonin is an ointment produced from Lithospermun erythrorhizon which has been used in traditional medicine both in Europe and Asia for wound healing and is associated with anti-inflammatory properties. "( "Shikonin inhibits microglia activation and reduces CFA-induced mechanical hyperalgesia in an animal model of pain".
Biscaia, M; Gomez, J; Grassi, D; Llorente, R; Vega-Avelaira, D, 2022
)
3.07
"Shikonin is a natural multipotent anti-tumorigenic compound. "( Synergy between sublethal doses of shikonin and metformin fully inhibits breast cancer cell migration and reverses epithelial-mesenchymal transition.
Gardaneh, M; Gavidel, P; Sabouni, F; Tabari, AR, 2022
)
2.44
"Shikonin is a naphthoquinone natural dye that is isolated from the plants of the Boraginaceae family and has proven its role as an anti-cancer, anti-inflammatory, and anti-gonadotrophic agent."( Investigation of antidiabetic properties of shikonin by targeting aldose reductase enzyme: In silico and in vitro studies.
Alabdallah, NM; Alam, MJ; Ansari, IA; Ansari, MJ; Badraoui, R; Bardakci, F; El Asmar, Z; Jamal, QMS; Saeed, M; Shoaib, A; Tasleem, M; Wang, F; Yadav, DK, 2022
)
1.7
"Shikonin is a naphthoquinone compound extracted from Chinese comfrey for treating cancer. "( Shikonin Inhibits Fin Regeneration in Zebrafish Larvae.
Cao, Z; Chen, G; Guo, C; Liao, X; Liu, F; Liu, J; Lu, H; Ni, H; Xiong, G, 2022
)
3.61
"Shikonin is a red naphthoquinone natural product from plants with high economical and medical values. "( Characterization of Arnebia euchroma PGT homologs involved in the biosynthesis of shikonin.
Guo, L; Liu, C; Liu, T; Navrot, N; Shen, Y; Shi, L; Tatsumi, K; Wang, J; Wang, R; Wang, S, 2023
)
2.58
"Shikonin is a well-known natural naphthazarin derivative with promising antifungal efficacy, but it's mechanism of action is still unclear."( In silico molecular modelling studies and antibiofilm efficacy of shikonin against Candida albicans: mechanistic insight.
Arora, S; Bedi, N; Kaur, H; Kaur, K; Kaur, R; Singh, A, 2023
)
1.87
"Shikonin is a natural product with antioxidant and anti-inflammatory activities. "( Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects.
Chen, X; Liang, Y; Lin, S; Xue, X; Yasen, M, 2023
)
2.66
"Shikonin is an active ingredient extracted from the roots of Lithospermum erythrorhizon, and exerts multiple anti-tumor functions in many cancers."( Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation.
Liu, H; Qian, X; Qin, J; Shao, Q; Xu, M; Yu, X; Zhu, L, 2023
)
3.07
"Shikonin is an anti-inflammatory natural herbal drug extracted from Lithospermum erythrorhizon and its therapeutic effect on neuropsychiatric systemic lupus erythematosus (NPSLE) is yet unknown. "( Systemic administration of Shikonin ameliorates cognitive impairment and neuron damage in NPSLE mice.
Dou, H; Hou, Y; Liang, J; Liu, X; Ni, J; Wang, H; Zhang, R, 2023
)
2.65
"Shikonin is a naphthoquinone compound extracted from the root of Lithospermum with various pharmacological activities. "( Shikonin attenuates sympathetic remodeling in chronic heart failure mice via regulating miR-124.
Liu, Q; Liu, WL, 2019
)
3.4
"Shikonin is a natural naphthoquinone component with antioxidant and anti-tumor function and has been used for hepatocellular carcinoma (HCC) treatment. "( Shikonin suppresses progression and epithelial-mesenchymal transition in hepatocellular carcinoma (HCC) cells by modulating miR-106b/SMAD7/TGF-β signaling pathway.
Li, X; Zeng, X, 2020
)
3.44
"Shikonin is a naturally extracted naphthoquinone pigment with effects against cancer, including colon cancer."( Shikonin-induced Apoptosis of Colon Cancer Cells Is Reduced by Peroxiredoxin V Expression.
Chandimali, N; Kong, LZ; Kwon, T; Lee, DS; Liu, R; Sun, HN; Zhen, X, 2019
)
2.68
"Shikonin is an anti-inflammatory agent extracted from natural herbs. "( Shikonin improve sepsis-induced lung injury via regulation of miRNA-140-5p/TLR4-a vitro and vivo study.
Liu, X; Zhang, J; Zhang, X; Zhang, YY, 2020
)
3.44
"Shikonin is a bioactive constitute of Chinese traditional herb which plays a role in antimicrobial and antitumor activities."( Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Cai, M; Chen, K; Chen, Z; Huang, C; Li, B; Li, M; Wang, Y; Wei, X; Yan, Z; Yang, C; Yang, M; Yang, Y; Zhai, X; Zhou, X, 2020
)
2.72
"Shikonin is a promising candidate for treatment of postmenopausal osteoporosis."( Shikonin mitigates ovariectomy-induced bone loss and RANKL-induced osteoclastogenesis via TRAF6-mediated signaling pathways.
Cai, M; Chen, K; Chen, Z; Huang, C; Li, B; Li, M; Wang, Y; Wei, X; Yan, Z; Yang, C; Yang, M; Yang, Y; Zhai, X; Zhou, X, 2020
)
2.72
"Shikonin is a natural naphthoquinone derivative that specifically occurs in boraginaceous plants, and the major active ingredient of the medicinal plant Lithospermum erythrorhizon. "( Potential role of two cytochrome P450s obtained from Lithospermum erythrorhizon in catalyzing the oxidation of geranylhydroquinone during Shikonin biosynthesis.
Liu, T; Song, W; Zhuang, Y, 2020
)
2.2
"Shikonin is a Traditional Chinese herbal medicine, which has been reported to exert antitumor effects."( Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.
Liu, Y; Lv, Z; Sha, L; Sui, X; Wang, T; Zhang, H; Zhang, Y, 2021
)
2.79
"Shikonin is a naphthoquinone extracted from the root of Lithospermum erythrorhizon, and has been reported to suppress allergic airway inflammation in mice. "( Shikonin alleviates allergic airway remodeling by inhibiting the ERK-NF-κB signaling pathway.
Li, M; Shang, YX; Wang, TY; Zhou, QL, 2017
)
3.34
"Shikonin is a bioactive compound with anti-inflammatory, antiviral, and antibacterial activities derived from the roots of the Chinese medicinal herb Lithospermum erythrorhizon."( Antiviral activity of shikonin ester derivative PMM-034 against enterovirus 71 in vitro.
Han, H; Lin, H; Lu, G; Pang, Y; Qi, J; Qiu, H; Sun, L; Wang, X; Yang, R; Yang, Y; Yu, L; Zhang, Y; Zhu, W, 2017
)
1.49
"Shikonin (SHK) is a highly liposoluble naphthoquinone pigment has recently been investigated as a potential antiglioma agent. "( Lactoferrin functionalized PEG-PLGA nanoparticles of shikonin for brain targeting therapy of glioma.
Bai, L; Duan, X; Li, H; Tong, Y; Ye, L; Zhong, L; Zhu, Y, 2018
)
2.17
"Shikonin is a naphthoquinone pigment extracted from roots of Lithospermum erythrorhizon Sieb. "( Assessment of the inhibition risk of shikonin on cytochrome P450 via cocktail inhibition assay.
Chen, A; Liu, M; Tang, S; Wang, X; Zeng, L; Zhou, X, 2017
)
2.17
"Shikonin is a naphthoquinone secondary metabolite with important medicinal value and is found in Lithospermum erythrorhizon. "( Involvement of LeMDR, an ATP-binding cassette protein gene, in shikonin transport and biosynthesis in Lithospermum erythrorhizon.
Bian, ZW; Lu, GH; Pang, YJ; Qi, JL; Tang, CY; Wang, XM; Wu, FY; Yang, RW; Yang, YH; Zhu, Y, 2017
)
2.14
"Shikonin is a naphthoquinone isolated from the dried root of Lithospermum erythrorhizon, an herb used in Chinese medicine. "( RNA-seq transcriptome analysis of breast cancer cell lines under shikonin treatment.
Chen, CS; Cheng, WC; Fang, SH; Huang, MY; Hung, YL; Li, CY; Lin, KH; Liu, PL; Su, CC; Tu, HP; Wang, SC; Wang, YT, 2018
)
2.16
"Shikonin (SHK) is a natural naphthoquinone derivative from a Chinese herb."( Excessive Oxidative Stress in the Synergistic Effects of Shikonin on the Hyperthermia-Induced Apoptosis.
Cui, ZG; Feng, QW; Inadera, H; Jin, YJ; Kondo, T; Li, ML; Piao, JL; Sun, L; Zakki, SA; Zhou, D, 2018
)
1.45
"Shikonin is a natural product with antioxidant and anti-inflammatory activities."( Shikonin attenuates acetaminophen-induced acute liver injury via inhibition of oxidative stress and inflammation.
Chen, F; Guo, H; Hu, Y; Hua, H; Jia, Z; Jing, X; Li, D; Sun, J; Xu, J; Yu, X, 2019
)
2.68
"Shikonin is a natural compound isolated from herbs and traditional medicines that have been used in a number of countries to treat various illnesses including inflammation, virus infection and cancer for centuries. "( Synthesis, biological function and evaluation of Shikonin in cancer therapy.
Tang, J; Wang, F; Yao, X; Zhang, Y, 2019
)
2.21
"Shikonin is an active compound of the oriental medicinal plant, Leptospermum erythrorhizon, which has been previously shown to inhibit psoriasis-like inflammation. "( Shikonin induces apoptosis and suppresses growth in keratinocytes via CEBP-δ upregulation.
Gao, XH; Geng, L; Lan, XO; Liu, XY; Xu, YY; Yu, YJ; Zhang, XL, 2019
)
3.4
"Shikonin is a traditional Oriental medical herb extracted from Lithospermum erythrorhizon. "( Shikonin suppresses the migratory ability of hepatocellular carcinoma cells.
Chang, YJ; Chen, CH; Chen, WY; Ho, YS; Liu, JJ; Su, HY; Tu, CC; Wei, PL; Wu, CT, 2013
)
3.28
"Shikonin, which is an active naphthoquinone isolated from traditional Chinese herbal medicine Zi Cao, has been recently developed to use as an antitumor agent in colorectal cancer, melanoma, leukemia, breast cancer, and hepatocellular cancer. "( Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways.
Guan, H; Hou, P; Ji, M; Shi, B; Yang, Q, 2013
)
3.28
"Shikonin is a quinone-containing natural product that induces the apoptotic death of some cancer cell lines in culture through increasing intracellular reactive oxygen species (ROS). "( An oxidative stress mechanism of shikonin in human glioma cells.
Chen, CH; Li, ZL; Lu, FJ; Wu, JY; Yang, JT, 2014
)
2.13
"Shikonin is a compound from the herbal plant Lithospermum erythrorhizon that has been proved to possess powerful anti-proliferative effect on many kinds of cancers and to be safe in in vivo study. "( Shikonin inhibits the proliferation of human lens epithelial cells by inducing apoptosis through ROS and caspase-dependent pathway.
Huang, WR; Tang, X; Zhang, Y, 2014
)
3.29
"Shikonin is an active naphthoquinone pigment isolated from the root of Lithospermum erythrorhizon. "( Shikonin inhibits the cell viability, adhesion, invasion and migration of the human gastric cancer cell line MGC-803 via the Toll-like receptor 2/nuclear factor-kappa B pathway.
Cui, L; Gu, JF; Liu, D; Liu, JP; Zhu, MM, 2015
)
3.3
"Shikonin is a naphthoquinone compound extracted from the Chinese herb purple gromwell. "( Shikonin inhibits TNF-α-induced growth and invasion of rat aortic vascular smooth muscle cells.
Hu, J; Hu, W; Wu, F; Yuan, X; Zhang, X, 2015
)
3.3
"Shikonin is a major active chemical component extracted from Lithospermi Radix, an effective traditional herb in various types of wound healing. "( Shikonin Promotes Skin Cell Proliferation and Inhibits Nuclear Factor-κB Translocation via Proteasome Inhibition In Vitro.
Furumura, M; Gouya, T; Hashimoto, T; Iwanaga, A; Karashima, T; Li, XG; Numata, S; Teye, K; Yan, Y, 2015
)
3.3
"Shikonin is a naturally occurring naphthoquinone pigment and a major constituent present in Lithospermum erythrorhizon. "( Shikonin inhibits adipogenic differentiation via regulation of mir-34a-FKBP1B.
Ahn, J; Gwon, SY; Ha, TY; Jang, YJ; Jung, CH, 2015
)
3.3
"Shikonin is an anthraquinone derivative extracted from the root of lithospermum. "( Shikonin Inhibits the Migration and Invasion of Human Glioblastoma Cells by Targeting Phosphorylated β-Catenin and Phosphorylated PI3K/Akt: A Potential Mechanism for the Anti-Glioma Efficacy of a Traditional Chinese Herbal Medicine.
Hu, Y; Liu, YH; Que, ZY; Wang, P; Wang, ZH; Xue, YX; Zhang, FY, 2015
)
3.3
"Shikonin, which is a major ingredient of the traditional Chinese herb Lithospermum erythrorhizon, possesses various biological functions, including antimicrobial, anti-inflammatory, and antitumor activities. "( Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways.
Fan, J; Guo, J; Jia, J; Jing, H; Li, J; Luo, S; Sun, W; Yang, J; Zhang, Y; Zheng, Y, 2016
)
3.32
"Shikonin is a naphthoquinone isolated from the traditional Chinese medicine Lithospermum. "( Shikonin Inhibits the Proliferation of Human Breast Cancer Cells by Reducing Tumor-Derived Exosomes.
Cui, S; Li, L; Li, M; Wang, D; Wei, Y; Zen, K; Zhang, CY, 2016
)
3.32
"Shikonin is a highly lipophilic naphtoquinone found in the roots of Lithospermum erythrorhizon used for its pleiotropic effects in traditional Chinese medicine. "( Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1.
Hafner-Bratkovič, I; Sušjan, P; Zorman, J, 2016
)
3.32
"Shikonin is a natural compound that is known to have antitumor effects."( SIRT2 mediated antitumor effects of shikonin on metastatic colorectal cancer.
Chen, YJ; Hu, XM; Jin, YD; Min, ZL; Wang, Q; Wei, C; Wu, QM; Yuan, Q; Zhan, L; Zhang, LL, 2017
)
1.45
"Shikonin is a kind of naphthoquinone compound found mainly in Lithospermum erythrorhizon Sieb,et Zucc. "( Enhancement of NK cells proliferation and function by Shikonin.
Cao, T; Chen, C; Gu, Y; Hu, C; Li, Y; Lu, H; Ning, Z; Tao, M, 2017
)
2.15
"Shikonin is a major component of Radix Lithospermi and has various biological activities."( Anti-adenovirus activities of shikonin, a component of Chinese herbal medicine in vitro.
Chen, G; Gao, CY; Gao, H; Jiang, FY; Liu, L; Qin, L; Qu, ZY; Shang, L; Wang, SQ; Wang, YC; Wei, FX, 2011
)
1.38
"Shikonin is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities, including inhibition of human immunodeficiency virus (HIV) type 1 (HIV-1). "( Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1.
Buckheit, RW; Chen, X; Howard, OM; Oppenheim, JJ; Osterling, C; Turpin, JA; Yang, L; Zhang, N, 2003
)
3.2
"Shikonin is a main constituent of the roots of Lithospermum erythrorhizon that has antimutagenic activity. "( Induction of apoptosis by shikonin through coordinative modulation of the Bcl-2 family, p27, and p53, release of cytochrome c, and sequential activation of caspases in human colorectal carcinoma cells.
Hsu, PC; Huang, YT; Lin, JK; Pan, MH; Tsai, ML; Wang, YJ, 2004
)
2.07
"Shikonin is a red naphthazarin pigment derived from the roots of Lithospermum erythorhizon and produced biotechnologically by cell cultures."( [Cytochrome P450 enzymes in biosyntheses of some plant secondary metabolites].
Inoue, K, 2005
)
1.05
"Shikonin is a chemically characterized component of traditional Chinese herbal medicine and has been shown to possess antiinflammatory activities. "( Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1.
Chen, X; Howard, OM; Oppenheim, J, 2001
)
3.2

Effects

Shikonin (SHK) has multifaceted physiological functions, including antitumor, anti-inflammatory, and antimicrobial effects. It has impacts on the development of hypertrophic scars (HS), however, these effects are yet mostly unknown.

ExcerptReferenceRelevance
"Shikonin (SHK) has multifaceted physiological functions, including antitumor, anti-inflammatory, and antimicrobial effects. "( Shikonin impairs T lymphocyte proliferation and thymopoiesis while it may increase myeloid-derived suppressor cells to alleviate immune responses.
Fang, MH; Su, L; Tian, HM; Zou, J, 2022
)
3.61
"Shikonin has impacts on the development of hypertrophic scars (HS), however, these effects are yet mostly unknown."( The effects of Shikonin on the hypertrophic scar of rabbit ears via the TLR4/NF-κB signaling pathway.
Cui, X; Liu, C; Wang, S; Zhang, H; Zhou, Q, 2023
)
1.98
"Shikonin has been demonstrated to show anti-cancer activity in many cancer types."( Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.
Jiang, H; Rao, Y; Wu, Z; Zang, F; Zhu, X, 2020
)
2.72
"Shikonin has been demonstrated to play the antitumor effect in various cancers."( Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway.
Xiao, S; Zhang, J; Zhou, J, 2020
)
2.72
"Shikonin (SHK) has been proven to have a good anti-tumor effect. "( Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells.
Cai, D; Fan, L; Li, J; Sun, J; Wang, Q; Wen, X; Wu, Y; Yue, L; Zhou, L, 2018
)
2.21
"Shikonin has been reported to inhibit lymphangiogenesis in vitro, but the mechanism of inhibition has not been determined."( Shikonin Suppresses Lymphangiogenesis via NF-κB/HIF-1α Axis Inhibition.
Jantaree, P; Koizumi, K; Lirdprapamongkol, K; Prangsaengtong, O; Svasti, J, 2018
)
2.64
"Shikonin has gained attention for its prominent anti-inflammatory property, but up to now little is known about shikonin treatment in acute ischemic stroke."( Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-κB, TNF-α and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability.
Chen, L; Cui, L; Li, Z; Miao, J; Qiao, H; Wang, L; Wang, S; Zhang, X; Zhu, C, 2014
)
1.44
"Shikonin has broad antibacterial, anti-inflammatory, and antitumor activities."( Shikonin inhibits TNF-α-induced growth and invasion of rat aortic vascular smooth muscle cells.
Hu, J; Hu, W; Wu, F; Yuan, X; Zhang, X, 2015
)
2.58
"Shikonin has recently been reported to have several pharmacological properties, e.g., it has anti-microbial, anti-tumor, and anti-inflammatory effects."( Shikonin Inhibits Inflammatory Cytokine Production in Human Periodontal Ligament Cells.
Hosokawa, I; Hosokawa, Y; Matsuo, T; Ozaki, K; Shindo, S, 2016
)
2.6
"Shikonin has been reported to induce glioma cell death via necroptosis, a type of programmed necrosis primarily mediated by RIP1 and RIP3. "( RIP1 and RIP3 contribute to shikonin-induced DNA double-strand breaks in glioma cells via increase of intracellular reactive oxygen species.
Chi, G; Ge, P; Lu, B; Luo, T; Luo, Y; Meng, F; Piao, M; Wang, C; Wang, Z; Zhou, Z, 2017
)
2.19
"Shikonin has been reported to have antibacterial, antitumor, and anti-inflammatory effects."( Shikonins attenuate microglial inflammatory responses by inhibition of ERK, Akt, and NF-kappaB: neuroprotective implications.
Lee, EH; Nam, KN; Park, JH; Son, MS, 2008
)
2.51
"Shikonin (SK) has been isolated and identified as a key bioactive component in an herbal plant, Shikon (gromwell). "( A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells.
Yao, Y; Zhou, Q, 2010
)
2.1
"Shikonin has anticancer activity, but it has not yet been applied into clinical use. "( Preparation, cellular uptake and angiogenic suppression of shikonin-containing liposomes in vitro and in vivo.
Gui, H; Qi, J; Tang, C; Wang, X; Xia, H; Yang, Y, 2013
)
2.08
"Shikonin has been demonstrated to exhibit anti-cancer activity, but the underlying mechanisms are poorly understood. "( Involvement of reactive oxygen species, but not mitochondrial permeability transition in the apoptotic induction of human SK-Hep-1 hepatoma cells by shikonin.
Chen, CH; Chern, CL; Hsieh, PY; Lin, CC; Liu, TZ; Lu, FJ; Shih, MK, 2003
)
1.96
"Shikonin has the potential to prevent, or be used in the treatment of, bladder transitional cell carcinoma induced by arylamines. "( The inhibition of N-acetyltransferase activity and gene expression in human bladder cancer cells (T24) by shikonin.
Chung, JG; Li, TM; Lin, SY; Wu, LT; Yeh, CC,
)
1.79
"Shikonin has been shown to induce apoptosis and inhibit angiogenesis in vivo and in vitro."( Shikonin inhibits the growth and N-acetylation of 2-aminofluorene in Helicobacter pylori from ulcer patients.
Chuang, YC; Chung, JG; Hsia, TC; Kuo, HM; Lin, SY; Lu, HF,
)
2.3
"Shikonin has been reported to induce apoptosis and inhibit angiogenesis in vivo and in vitro. "( DMNQ S-64 induces apoptosis via caspase activation and cyclooxygenase-2 inhibition in human nonsmall lung cancer cells.
Ahn, KS; Kang, H; Kim, SH; Lim, ES; Park, MK; Rhee, YH; Shim, BS; Yoo, HS, 2007
)
1.78

Actions

Shikonin could enhance apoptosis and inhibit proliferation and invasion of QBC939 cells. It did not inhibit monocyte chemoattractant protein-1 (MCP-1) binding to CCR2 cells. Shikon in could inhibit HaCaT cells proliferation induced by IL-17 and secretion of relevant cytokines.

ExcerptReferenceRelevance
"Shikonin might inhibit such responses by regulating ER stress through the protein kinase-like ER kinase-eukaryotic translation initiation factor 2 α-subunit-C/EBP homologous protein (PERK-eIF2α-CHOP) signalling pathway."( Shikonin inhibits neuronal apoptosis via regulating endoplasmic reticulum stress in the rat model of double-level chronic cervical cord compression.
Cui, XJ; Li, G; Liu, SF; Sun, YL; Wang, YJ; Yao, M; Zheng, Z; Zhou, LY, 2023
)
3.07
"Shikonin plays a pivotal role in redox status, but whether it can regulate ferroptosis to treat TP remains unknown."( Shikonin Could Be Used to Treat Tubal Pregnancy via Enhancing Ferroptosis Sensitivity.
Chen, Z; Deng, G; Feng, M; Gao, J; Huang, Y; Ke, Y; Lai, Y; Qiu, P; Zeng, F; Zeng, L, 2022
)
2.89
"Shikonin plays protective roles in age-associated diseases."( Shikonin ameliorates oxidative stress and neuroinflammation via the Akt/ERK/JNK/NF-κB signalling pathways in a model of Parkinson's disease.
Du, J; Guo, L; Li, W; Li, Y; Qiu, J; Wang, L; Zhang, T, 2022
)
2.89
"Shikonin can suppress compound 48/80 (C48/80)-induced PCA, active systemic anaphylaxis, and MCs degranulation in mice in a dose-dependent manner. "( Inhibitory function of Shikonin on MRGPRX2-mediated pseudo-allergic reactions induced by the secretagogue.
An, H; Ding, Y; Hu, S; Li, C; Wang, J; Zhang, Y, 2020
)
2.31
"Shikonin could enhance apoptosis and inhibit proliferation and invasion of QBC939 cells; such biological behaviors mainly occurred via upregulating the expression of caspase-3 and caspase-8 and downregulating the expression of MMP-9 and EGFR."( Shikonin Inhibits Cholangiocarcinoma Cell Line QBC939 by Regulating Apoptosis, Proliferation, and Invasion.
Feng, Z; Ji, XD; Li, K; Li, XJ; Liu, C; Lv, C; Shen, J; Wan, R; Xuan, LQ,
)
2.3
"Shikonin can enhance the CD36 expression and the ability to phagocytose erythrocyte of microglia. "( Study on the effect of shikonin on CD36 expression and phagocytic ability of microglia in the isolated cerebral haemorrhage model.
Gong, F; Huang, Y; Nie, S; Zhao, F; Zhao, J; Zhou, C, 2021
)
2.37
"Shikonin plays a significant protective role in ischemia/reperfusion injury."( The protective effects of shikonin on hepatic ischemia/reperfusion injury are mediated by the activation of the PI3K/Akt pathway.
Chen, K; Cheng, K; Dai, W; Feng, J; Guo, C; Kong, R; Li, J; Li, L; Li, S; Liu, T; Lu, J; Lu, X; Mo, W; Wang, F; Wu, L; Xia, Y; Xu, S; Yu, Q; Zhang, Q; Zhang, R; Zhao, Y; Zhou, S; Zhou, Y, 2017
)
1.48
"Shikonin can inhibit K1 and W3 cell proliferation in a dose- and time-dependent manner, enhance Bax levels, reduce anti-apoptotic protein Bcl-2 levels, result in decreasing mitochondrial membrane potential and activating caspase-3 enzyme, and finally lead to apoptosis."( The apoptotic effect of shikonin on human papillary thyroid carcinoma cells through mitochondrial pathway.
Chen, J; Liu, C; Yin, L, 2014
)
1.43
"Shikonin could inhibit HaCaT cells proliferation induced by IL-17 and secretion of relevant cytokines and recruit leukocytes by inhibiting chemokines, so as to show the effect in treating psoriasis."( [Effect of shikonin on proliferation of keratinocytes induced by interleukin-17 and expression of chemokines].
Li, P; Lin, Y; Liu, X; Xie, XR; Zhang, L, 2015
)
2.25
"Shikonin was found to inhibit fat droplet formation and triglyceride accumulation in 3T3-L1 adipocytes."( Shikonin inhibits fat accumulation in 3T3-L1 adipocytes.
Kang, R; Lee, H; Yoon, Y, 2010
)
2.52
"Shikonin could inhibit the proliferation of HL-60 cells with the concentration range of 1-8 microg/mL in a time- and concentration-dependent manner. "( [Effects of shikonin on the proliferation and apoptosis of HL-60 cells].
Chen, ZL; Dai, QZ; Wang, Y, 2012
)
2.2
"Shikonin can inhibit the proliferation of HASMCs in vitro."( [Shikonin inhibits the proliferation of human airway smooth muscle cells].
Lai, WY; Li, ZX; Luo, YL; Ren, DQ; Xu, J; Zhao, YX, 2008
)
2.7
"Shikonin also did not inhibit monocyte chemoattractant protein-1 (MCP-1) binding to CCR2 cells, eotaxin binding to CCR3 cells, interferon-inducible T cell alpha-chemoattractant (I-TAC) binding to CXCR3 cells and SDF-1alpha binding to CXCR4 cells."( Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1.
Chen, X; Howard, OM; Oppenheim, J, 2001
)
2.47

Treatment

Shikonin treatment effectively suppressed the activation of ERK, the expression of ferroptosis inhibitor GPX4, and elevated the level of 4-HNE, a biomarker of ferraptosis. The drug also alleviated D-gal-induced memory impairment and reversed the D-Gal-induced neural damage and apoptosis.

ExcerptReferenceRelevance
"Shikonin treatment resulted in a notable improvement in the histopathological manifestations in DSS-treated animals at 25/50 mg/kg."( Experimental evidence of shikonin as a novel intervention for anti-inflammatory effects.
Chen, X; Liang, Y; Lin, S; Xue, X; Yasen, M, 2023
)
1.93
"Shikonin treatment effectively suppressed the activation of ERK, the expression of ferroptosis inhibitor GPX4, and elevated the level of 4-HNE, a biomarker of ferroptosis."( Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation.
Liu, H; Qian, X; Qin, J; Shao, Q; Xu, M; Yu, X; Zhu, L, 2023
)
3.07
"Shikonin treatment, however, alleviated D-gal-induced memory impairment and reversed the D-gal-induced neural damage and apoptosis."( Shikonin ameliorates D-galactose-induced oxidative stress and cognitive impairment in mice via the MAPK and nuclear factor-κB signaling pathway.
Chen, K; Li, T; Shen, C; Tang, Q; Wang, Z; Xie, Q; Zhong, J; Zhu, J; Zhu, T, 2020
)
2.72
"Shikonin treatment effectively inhibits the growth of human TNBC cell line MDA-MB-231, and murine TNBC cell line, 4T1 in a dose-dependent manner, which is impaired by exogenous supplementation of guanosine, a salvage pathway of purine nucleotides."( Shikonin is a novel and selective IMPDH2 inhibitor that target triple-negative breast cancer.
Chen, S; He, J; Huang, J; Liu, X; Lu, W; Tang, Y; Wang, S; Wang, W; Wu, Y, 2021
)
2.79
"But, shikonin treatment significantly reduced the expression levels of TNF-α, IFN-γ and Bax."( Shikonin ameliorates experimental autoimmune encephalomyelitis (EAE) via immunomodulatory, anti-apoptotic and antioxidative activity.
Biglari, S; Esmaeilzadeh, E; Khorram Khorshid, HR; Nasrollahzadeh Sabet, M, 2020
)
2.46
"Shikonin treatment attenuated the above biochemical and histopathological changes."( Effects of shikonin from Zicao on high-fat diet-induced nonalcoholic fatty liver disease in rats.
Ma, Y; Ren, X; Teng, L; Wang, T; Yang, M; Yang, W; Yao, H, 2020
)
1.67
"Shikonin treatment decreased the proliferation, migration, invasion, glucose uptake, lactate levels, ATP levels and PFKFB2 expression levels and increased apoptosis in lung cancer cells in a dose‑dependent manner."( Shikonin inhibits the Warburg effect, cell proliferation, invasion and migration by downregulating PFKFB2 expression in lung cancer.
Liu, Y; Lv, Z; Sha, L; Sui, X; Wang, T; Zhang, H; Zhang, Y, 2021
)
2.79
"Shikonin treated C6 glioma cells presented electron-lucent cytoplasm, loss of plasma membrane integrity and intact nuclear membrane in morphology."( Shikonin kills glioma cells through necroptosis mediated by RIP-1.
Fan, W; Ge, P; Huang, C; Luo, Y; Yang, F; Zhao, H; Zhao, J, 2013
)
2.55
"Shikonin pretreatment also decreased the activity of IL-1β that decreased Bcl-2 expression and levels of p-PI3K and p-Akt, and increased Bax expression, cytochrome c release, and caspase-3 activation."( Shikonin protects chondrocytes from interleukin-1beta-induced apoptosis by regulating PI3K/Akt signaling pathway.
Gai, P; Li, Y; Liu, S; Lv, S; Wang, L; Xu, R; Zheng, Y, 2015
)
2.58
"Shikonin treated mice fed regular chow exhibited improved glucose tolerance compared with controls. "( Decreased adiposity and enhanced glucose tolerance in shikonin treated mice.
Abdulaziz, A; Bettaieb, A; Chahed, S; Gaikwad, NW; Haj, FG; Hosein, E; Kucera, HR, 2015
)
2.11
"Shikonin (5 mg/kg) treatment along had no effect on macroscopic score and incidence of arthritis on early stage of CIA. "( Dual role of shikonin in early and late stages of collagen type II arthritis.
Dai, Q; Fang, J; Zhang, FS, 2009
)
2.16
"Shikonin treatment on established CIA can inhibit Th1 cytokines expression and induce Th2 cytokines expression in mice with established CIA. "( Dual role of shikonin in early and late stages of collagen type II arthritis.
Dai, Q; Fang, J; Zhang, FS, 2009
)
2.16
"Shikonin treatment resulted in tumor growth inhibition in both H22 allografts and PC-3 xenografts, associated with suppression of the proteasomal activity and induction of cell death in vivo."( Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo.
Chen, D; Cui, QC; Dong, W; Dou, QP; Huang, H; Lian, W; Liu, J; Ma, N; Shen, S; Wang, X; Yang, H; Zhang, X; Zhou, P, 2009
)
2.52
"Shikonin-treated BM-DCs were poor stimulators of CD4(+) T lymphocyte and induced lower levels of interleukin (IL)-4, IL-5, IL-13 and tumour necrosis factor (TNF)-α release by responding T-cells."( Shikonin inhibits maturation of bone marrow-derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthma.
Chen, HC; Cheng, YW; Chiang, BL; Kang, JJ; Lai, YT; Lee, CC; Liao, JW; Wang, CN, 2010
)
2.52
"Shikonin treatment alone could slightly inhibit the phosphorylation of ERK1/2 in leukemia cells, and the inhibitory effect on ERK1/2 was significantly augmented by Nec-1."( Nec-1 enhances shikonin-induced apoptosis in leukemia cells by inhibition of RIP-1 and ERK1/2.
Fang, Y; Han, W; Pan, H; Wang, Z; Xie, J, 2012
)
1.45
"Shikonin pretreatment significantly attenuated LPS-induced pulmonary histopathologic changes, alveolar hemorrhage, and neutrophil infiltration. "( Shikonin attenuates lipopolysaccharide-induced acute lung injury in mice.
Bai, GZ; Ke, CK; Lei, J; Li, XF; Liu, BY; Ni, YF; Su, K; Wang, YJ; Yu, HT; Zhang, ZP; Zhao, JB; Zhong, DX, 2013
)
3.28
"Treatment with shikonin derivatives caused an inhibition of pSTAT3 and an increase in pAKT, pERK, pJNK, and pp38."( The Biological Assessment of Shikonin and β,β-dimethylacrylshikonin Using a Cellular Myxofibrosarcoma Tumor Heterogeneity Model.
Eck, N; Glänzer, D; Kaltenegger, H; Kretschmer, N; Leithner, A; Lohberger, B, 2023
)
1.54
"Treatment with shikonin, a well-used necroptosis inducer, markedly caused necroptosis in HCC cells."( Connexin32 activates necroptosis through Src-mediated inhibition of caspase 8 in hepatocellular carcinoma.
Cai, SY; Fan, LX; Ge, H; Guo, YQ; Peng, FH; Peng, YX; Tao, L; Wang, Q; Wen, H; Xiang, YK, 2021
)
0.96
"Treatment with shikonin (2-10 μmol/L) dose-dependently triggered necrosis and induced overproduction of intracellular ROS in rat C6 and human SHG-44, U87 and U251 glioma cell lines."( Shikonin induces glioma cell necroptosis in vitro by ROS overproduction and promoting RIP1/RIP3 necrosome formation.
Chi, GF; Ding, Y; Ge, PF; Gong, X; Lu, B; Luo, TF; Luo, YN; Meng, FK; Piao, MH; Wang, C; Wang, ZQ, 2017
)
2.24
"Treatment of shikonin also decreased tumor cell ATP production."( Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Hu, J; Jia, S; Jiang, L; Li, L; Zen, K; Zhao, X; Zhu, Y, 2018
)
2.28
"Pretreatment with shikonin (intraperitoneal injection) significantly inhibited LPS-induced increases in the macrophage and neutrophil infiltration of lung tissues and markedly attenuated myeloperoxidase activity."( Shikonin exerts anti-inflammatory effects in a murine model of lipopolysaccharide-induced acute lung injury by inhibiting the nuclear factor-kappaB signaling pathway.
Cao, Y; Fu, Y; Guo, M; Li, F; Liang, D; Liu, Z; Shen, Y; Song, X; Sun, Y; Yang, Z; Zhang, N; Zhao, F; Zhou, E, 2013
)
2.16
"Pretreatment with shikonin significantly increased the SOD and CAT activities and the ratio of GSH/GSSG in mouse brain tissues compared with irradiated group (P<0.01), while obviously reduced the MDA and PCO contents and the ROS levels derived from of the brain mitochondria."( Protective effects of shikonin on brain injury induced by carbon ion beam irradiation in mice.
Gan, L; Liu, Y; Liu, YY; Si, J; Sun, C; Wang, ZG; Wang, ZH; Zhang, H; Zhou, R, 2015
)
1.06
"Treatment with shikonin significantly inhibited the viability of HaCaT cells in a dose‑ and time‑dependent manner, and promoted cell cycle arrest at G0/G1 phase and apoptosis."( Shikonin induces apoptosis of HaCaT cells via the mitochondrial, Erk and Akt pathways.
Fan, J; Guo, J; Jia, J; Jing, H; Li, J; Luo, S; Sun, W; Yang, J; Zhang, Y; Zheng, Y, 2016
)
2.22
"Treatment with Shikonin for 14 weeks suppressed proteinuria dose-dependently with the mean proteinuria of 274.0 mg/dl and 160.3 mg/dl for low-dose and high-dose Shikonin groups, respectively, compared to 499.2 mg/dl for the vehicle."( Effects of shikonin isolated from zicao on lupus nephritis in NZB/W F1 mice.
Cao, LY; Fan, YS; Feng, J; Huang, F; Wang, XC; Wang, YY; Wen, CP, 2009
)
1.08
"Treatment with shikonin (10 mg/kg intraperitoneally) once daily for 4 days significantly decreased plasma glucose levels."( Shikonin increases glucose uptake in skeletal muscle cells and improves plasma glucose levels in diabetic Goto-Kakizaki rats.
Bengtsson, T; Csikasz, RI; Dehvari, N; Hutchinson, DS; Öberg, AI; Östenson, CG; Shabalina, IG; Wilcke, M; Yassin, K, 2011
)
2.15

Compound-Compound Interactions

ExcerptReferenceRelevance
" In this study, we investigated erlotinib in combination with shikonin and 14 shikonin derivatives in parental U87MG and transfected U87MG."( Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q, 2015
)
2.1

Bioavailability

Shikonin is a hydrophobic plant polyphenol with a variety of physiological activities. Complexing shik onin with β-lactoglobulin reduced toxicity while preserving inhibitory effect on NLRP3 inflammasome activation.

ExcerptReferenceRelevance
" Complexing shikonin with β-lactoglobulin reduced its toxicity while preserving the inhibitory effect on NLRP3 inflammasome activation, suggesting that shikonin with improved bioavailability might be interesting for therapeutic applications in inflammasome-mediated conditions."( Shikonin Suppresses NLRP3 and AIM2 Inflammasomes by Direct Inhibition of Caspase-1.
Hafner-Bratkovič, I; Sušjan, P; Zorman, J, 2016
)
2.26
" However, poor water solubility and low bioavailability limit its wide application in clinical practice."( Anticancer Efficacy of Targeted Shikonin Liposomes Modified with RGD in Breast Cancer Cells.
Cai, D; Fan, L; Li, J; Sun, J; Wang, Q; Wen, X; Wu, Y; Yue, L; Zhou, L, 2018
)
0.76
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"It is significant to develop a colloidal delivery system to improve the water solubility, stability, and bioavailability of shikonin, which is a hydrophobic plant polyphenol with a variety of physiological activities."( Improving shikonin solubility and stability by encapsulation in natural surfactant-coated shikonin nanoparticles.
Chen, W; Chen, X; Fang, S; He, J; Liu, C; Liu, W; Peng, S; Xie, Y; Zhong, J, 2023
)
1.52

Dosage Studied

Shikonin (10 and 25 mg/kg) was administered by gavage once a day for 3 days before surgery and another dosage after operation. DC vaccine preparations treated with tumor cells that were already pretreated with chloroquine and shik onin further enhanced the antimetastatic activity of 4T1 tumors.

ExcerptRelevanceReference
"The application of microcapsule for pharmaceutical dosage form for various drugs has received considerable attention in recent years due to its multiple advantages."( Microencapsulation of extract containing shikonin using gelatin-acacia coacervation method: a formaldehyde-free approach.
Cham, TM; Cheng, YH; Huang, YI; Tsai, TR; Yu, CC, 2007
)
0.61
" The effective dosage of GST in enhancement of cell proliferation was 10-50 nM, and the cell migration could be significantly enhanced after 6 hours in the presence of 2-50 nM GST."( Glutathione-S-transferase enhances proliferation-migration and protects against shikonin-induced cell death in breast cancer cells.
Chen, YT; He, S; Kuo, HM; Liao, TT; Lin, YL, 2011
)
0.6
" The data showed a strong dose-response relationship between Shikonin exposure and the characteristics of HL-60 differentiation in terms of morphology changes, nitroblue tetrazolium (NBT) reductive activity, and the expression level of surface antigens CD11b/CD14."( The critical role of redox homeostasis in shikonin-induced HL-60 cell differentiation via unique modulation of the Nrf2/ARE pathway.
Chen, H; Chen, N; Wang, Z; Zhang, B; Zheng, Q, 2012
)
0.88
" Shikonin (10 and 25 mg/kg) was administered by gavage once a day for 3 days before surgery and another dosage after operation."( Protective effect of shikonin in experimental ischemic stroke: attenuated TLR4, p-p38MAPK, NF-κB, TNF-α and MMP-9 expression, up-regulated claudin-5 expression, ameliorated BBB permeability.
Chen, L; Cui, L; Li, Z; Miao, J; Qiao, H; Wang, L; Wang, S; Zhang, X; Zhu, C, 2014
)
1.63
"5-100 ng/mL dosage of shikonin treatment on AGS cancer cell line with the incubation time of 6h."( Shikonin induces cell cycle arrest in human gastric cancer (AGS) by early growth response 1 (Egr1)-mediated p21 gene expression.
Chang, HI; Kim, JM; Kim, SJ; Shim, SH, 2014
)
2.16
" For potential clinical application, DC vaccine preparations treated with tumor cells that were already pretreated with chloroquine and shikonin further enhanced the antimetastatic activity of 4T1 tumors and reduced the effective dosage of doxorubicin."( Necroptosis promotes autophagy-dependent upregulation of DAMP and results in immunosurveillance.
Fan, YT; Hsiao, PW; Hsieh, SY; Lin, SY; Tsai, DH; Wei, WC; Wu, TS; Yang, NS, 2018
)
0.68
" However, the effective ICD requires a high dosage of ICD stimulus, which could be associated to a dose-dependent toxicity."( Low dose shikonin and anthracyclines coloaded liposomes induce robust immunogenetic cell death for synergistic chemo-immunotherapy.
Cai, W; He, Z; Kuang, X; Li, J; Liu, H; Wang, Y; Yang, Y; Yu, J; Zhou, S, 2021
)
1.04
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxy-1,4-naphthoquinoneAny member of the class of 1,4-naphthoquinones in which the naphthoquinone moiety is substituted by at least one hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency7.07950.003245.467312,589.2998AID2517
Chain A, ATP-DEPENDENT DNA HELICASE Q1Homo sapiens (human)Potency10.00000.125919.1169125.8920AID2549
Chain A, Ferritin light chainEquus caballus (horse)Potency28.18385.623417.292931.6228AID485281
phosphopantetheinyl transferaseBacillus subtilisPotency50.11870.141337.9142100.0000AID1490
PPM1D proteinHomo sapiens (human)Potency37.02590.00529.466132.9993AID1347411
Microtubule-associated protein tauHomo sapiens (human)Potency8.52810.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency15.84890.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency2.28380.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency6.30960.035520.977089.1251AID504332
runt-related transcription factor 1 isoform AML1bHomo sapiens (human)Potency0.39680.02007.985839.8107AID504370; AID504374; AID504375
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency1.77830.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency28.18380.010039.53711,122.0200AID1479
core-binding factor subunit beta isoform 2Homo sapiens (human)Potency0.39680.02007.985839.8107AID504370; AID504374; AID504375
DNA polymerase kappa isoform 1Homo sapiens (human)Potency0.89130.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency5.62340.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency25.11890.251215.843239.8107AID504327
Interferon betaHomo sapiens (human)Potency37.02590.00339.158239.8107AID1347411
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency7.07951.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Sterol O-acyltransferase 2Homo sapiens (human)IC50 (µMol)138.20000.11003.20369.2000AID305640
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)0.13920.00000.536910.0000AID1610897
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)15.74490.00022.45859.9600AID1845234; AID1845236
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)208.00000.02101.862610.0000AID56871
DNA topoisomerase 2-alphaHomo sapiens (human)IC50 (µMol)9.15000.48004.35649.9400AID1524651; AID1524652; AID1524653; AID1524654; AID1524655; AID1524656
Pyruvate kinase PKMHomo sapiens (human)IC50 (µMol)7.96000.50002.788610.0000AID1368254; AID1368255; AID1412789; AID1412790; AID1491463; AID1491464; AID1881860; AID1881865
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)25.00000.00053.49849.7600AID157217
Tyrosine-protein phosphatase 1Saccharomyces cerevisiae S288CIC50 (µMol)70.00001.20004.30007.4000AID220230
M-phase inducer phosphatase 1Homo sapiens (human)IC50 (µMol)0.22000.02204.20249.4000AID1517763
M-phase inducer phosphatase 2Homo sapiens (human)IC50 (µMol)0.40000.10002.31039.5100AID1517765
Pyruvate kinase PKLRHomo sapiens (human)IC50 (µMol)39.25000.20000.20000.2000AID1412803; AID1491466
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)70.40000.02501.79758.0000AID305641
DNA topoisomerase 2-betaHomo sapiens (human)IC50 (µMol)9.15000.03002.77167.8000AID1524651; AID1524652; AID1524653; AID1524654; AID1524655; AID1524656
Histone-lysine N-methyltransferase SETD7Homo sapiens (human)IC50 (µMol)21.62000.00202.52666.0800AID1667216
NeuraminidaseInfluenza A virus (A/Brevig Mission/1/1918(H1N1))IC50 (µMol)34.10000.00340.00340.0034AID644395
Class A sortase SrtA Staphylococcus aureusIC50 (µMol)2.65000.30002.86005.9000AID1494880; AID1494883
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA topoisomerase 1Homo sapiens (human)MIC50.00000.01002.00175.0000AID228426
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (215)

Processvia Protein(s)Taxonomy
cholesterol metabolic processSterol O-acyltransferase 2Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 2Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 2Homo sapiens (human)
intestinal cholesterol absorptionSterol O-acyltransferase 2Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 2Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 2Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 2Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 2Homo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
hematopoietic progenitor cell differentiationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-alphaHomo sapiens (human)
DNA ligationDNA topoisomerase 2-alphaHomo sapiens (human)
DNA damage responseDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome segregationDNA topoisomerase 2-alphaHomo sapiens (human)
female meiotic nuclear divisionDNA topoisomerase 2-alphaHomo sapiens (human)
apoptotic chromosome condensationDNA topoisomerase 2-alphaHomo sapiens (human)
embryonic cleavageDNA topoisomerase 2-alphaHomo sapiens (human)
regulation of circadian rhythmDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of apoptotic processDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIDNA topoisomerase 2-alphaHomo sapiens (human)
rhythmic processDNA topoisomerase 2-alphaHomo sapiens (human)
negative regulation of DNA duplex unwindingDNA topoisomerase 2-alphaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-alphaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-alphaHomo sapiens (human)
programmed cell deathPyruvate kinase PKMHomo sapiens (human)
canonical glycolysisPyruvate kinase PKMHomo sapiens (human)
positive regulation of sprouting angiogenesisPyruvate kinase PKMHomo sapiens (human)
positive regulation of cytoplasmic translationPyruvate kinase PKMHomo sapiens (human)
glycolytic processPyruvate kinase PKMHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKMHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of cyclin-dependent protein serine/threonine kinase activityM-phase inducer phosphatase 1Homo sapiens (human)
G1/S transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cell population proliferationM-phase inducer phosphatase 1Homo sapiens (human)
response to radiationM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
cellular response to UVM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of DNA replicationM-phase inducer phosphatase 1Homo sapiens (human)
cell divisionM-phase inducer phosphatase 1Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 1Homo sapiens (human)
G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
oocyte maturationM-phase inducer phosphatase 2Homo sapiens (human)
protein phosphorylationM-phase inducer phosphatase 2Homo sapiens (human)
female meiosis IM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cell population proliferationM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of cytokinesisM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of mitotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
cell divisionM-phase inducer phosphatase 2Homo sapiens (human)
positive regulation of G2/MI transition of meiotic cell cycleM-phase inducer phosphatase 2Homo sapiens (human)
response to hypoxiaPyruvate kinase PKLRHomo sapiens (human)
glycolytic processPyruvate kinase PKLRHomo sapiens (human)
response to nutrientPyruvate kinase PKLRHomo sapiens (human)
response to glucosePyruvate kinase PKLRHomo sapiens (human)
response to metal ionPyruvate kinase PKLRHomo sapiens (human)
response to ATPPyruvate kinase PKLRHomo sapiens (human)
pyruvate biosynthetic processPyruvate kinase PKLRHomo sapiens (human)
response to cAMPPyruvate kinase PKLRHomo sapiens (human)
cellular response to epinephrine stimulusPyruvate kinase PKLRHomo sapiens (human)
cellular response to insulin stimulusPyruvate kinase PKLRHomo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
neuron migrationDNA topoisomerase 2-betaHomo sapiens (human)
DNA topological changeDNA topoisomerase 2-betaHomo sapiens (human)
axonogenesisDNA topoisomerase 2-betaHomo sapiens (human)
B cell differentiationDNA topoisomerase 2-betaHomo sapiens (human)
forebrain developmentDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of single stranded viral RNA replication via double stranded DNA intermediateDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to hydrogen peroxideDNA topoisomerase 2-betaHomo sapiens (human)
cellular response to ATPDNA topoisomerase 2-betaHomo sapiens (human)
cellular senescenceDNA topoisomerase 2-betaHomo sapiens (human)
positive regulation of double-strand break repair via nonhomologous end joiningDNA topoisomerase 2-betaHomo sapiens (human)
sister chromatid segregationDNA topoisomerase 2-betaHomo sapiens (human)
resolution of meiotic recombination intermediatesDNA topoisomerase 2-betaHomo sapiens (human)
DNA damage responseHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin remodelingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine monomethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
peptidyl-lysine dimethylationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
response to ethanolHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
positive regulation of DNA-templated transcriptionHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
heterochromatin organizationHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (81)

Processvia Protein(s)Taxonomy
fatty-acyl-CoA bindingSterol O-acyltransferase 2Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
protein bindingSterol O-acyltransferase 2Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 2Homo sapiens (human)
acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 2Homo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
magnesium ion bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
RNA bindingDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-alphaHomo sapiens (human)
protein kinase C bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-alphaHomo sapiens (human)
ATP-dependent activity, acting on DNADNA topoisomerase 2-alphaHomo sapiens (human)
DNA binding, bendingDNA topoisomerase 2-alphaHomo sapiens (human)
protein homodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
ubiquitin bindingDNA topoisomerase 2-alphaHomo sapiens (human)
protein heterodimerization activityDNA topoisomerase 2-alphaHomo sapiens (human)
magnesium ion bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingPyruvate kinase PKMHomo sapiens (human)
mRNA bindingPyruvate kinase PKMHomo sapiens (human)
protein tyrosine kinase activityPyruvate kinase PKMHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKMHomo sapiens (human)
protein bindingPyruvate kinase PKMHomo sapiens (human)
ATP bindingPyruvate kinase PKMHomo sapiens (human)
MHC class II protein complex bindingPyruvate kinase PKMHomo sapiens (human)
potassium ion bindingPyruvate kinase PKMHomo sapiens (human)
cadherin bindingPyruvate kinase PKMHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 1Homo sapiens (human)
protein bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 1Homo sapiens (human)
protein-folding chaperone bindingM-phase inducer phosphatase 1Homo sapiens (human)
phosphoprotein phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein tyrosine phosphatase activityM-phase inducer phosphatase 2Homo sapiens (human)
protein bindingM-phase inducer phosphatase 2Homo sapiens (human)
protein kinase bindingM-phase inducer phosphatase 2Homo sapiens (human)
magnesium ion bindingPyruvate kinase PKLRHomo sapiens (human)
pyruvate kinase activityPyruvate kinase PKLRHomo sapiens (human)
protein bindingPyruvate kinase PKLRHomo sapiens (human)
ATP bindingPyruvate kinase PKLRHomo sapiens (human)
kinase activityPyruvate kinase PKLRHomo sapiens (human)
potassium ion bindingPyruvate kinase PKLRHomo sapiens (human)
monosaccharide bindingPyruvate kinase PKLRHomo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 2-betaHomo sapiens (human)
chromatin bindingDNA topoisomerase 2-betaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) activityDNA topoisomerase 2-betaHomo sapiens (human)
protein bindingDNA topoisomerase 2-betaHomo sapiens (human)
ATP bindingDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complex bindingDNA topoisomerase 2-betaHomo sapiens (human)
metal ion bindingDNA topoisomerase 2-betaHomo sapiens (human)
p53 bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
protein-lysine N-methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3 methyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
histone H3K4 monomethyltransferase activityHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromatin bindingHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
endoplasmic reticulumSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
brush borderSterol O-acyltransferase 2Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 2Homo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
centrioleDNA topoisomerase 2-alphaHomo sapiens (human)
chromosome, centromeric regionDNA topoisomerase 2-alphaHomo sapiens (human)
condensed chromosomeDNA topoisomerase 2-alphaHomo sapiens (human)
male germ cell nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
nucleolusDNA topoisomerase 2-alphaHomo sapiens (human)
cytoplasmDNA topoisomerase 2-alphaHomo sapiens (human)
DNA topoisomerase type II (double strand cut, ATP-hydrolyzing) complexDNA topoisomerase 2-alphaHomo sapiens (human)
protein-containing complexDNA topoisomerase 2-alphaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-alphaHomo sapiens (human)
nucleusDNA topoisomerase 2-alphaHomo sapiens (human)
extracellular regionPyruvate kinase PKMHomo sapiens (human)
nucleusPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
mitochondrionPyruvate kinase PKMHomo sapiens (human)
rough endoplasmic reticulumPyruvate kinase PKMHomo sapiens (human)
cytosolPyruvate kinase PKMHomo sapiens (human)
ciliumPyruvate kinase PKMHomo sapiens (human)
vesiclePyruvate kinase PKMHomo sapiens (human)
secretory granule lumenPyruvate kinase PKMHomo sapiens (human)
collagen-containing extracellular matrixPyruvate kinase PKMHomo sapiens (human)
extracellular exosomePyruvate kinase PKMHomo sapiens (human)
extracellular vesiclePyruvate kinase PKMHomo sapiens (human)
ficolin-1-rich granule lumenPyruvate kinase PKMHomo sapiens (human)
cytoplasmPyruvate kinase PKMHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 1Homo sapiens (human)
cytosolM-phase inducer phosphatase 1Homo sapiens (human)
nucleusM-phase inducer phosphatase 1Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 1Homo sapiens (human)
spindle poleM-phase inducer phosphatase 2Homo sapiens (human)
nucleoplasmM-phase inducer phosphatase 2Homo sapiens (human)
centrosomeM-phase inducer phosphatase 2Homo sapiens (human)
cytosolM-phase inducer phosphatase 2Homo sapiens (human)
nucleusM-phase inducer phosphatase 2Homo sapiens (human)
cytoplasmM-phase inducer phosphatase 2Homo sapiens (human)
cytosolPyruvate kinase PKLRHomo sapiens (human)
extracellular exosomePyruvate kinase PKLRHomo sapiens (human)
cytoplasmPyruvate kinase PKLRHomo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
heterochromatinDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmDNA topoisomerase 2-betaHomo sapiens (human)
nucleolusDNA topoisomerase 2-betaHomo sapiens (human)
cytosolDNA topoisomerase 2-betaHomo sapiens (human)
ribonucleoprotein complexDNA topoisomerase 2-betaHomo sapiens (human)
nucleusDNA topoisomerase 2-betaHomo sapiens (human)
nucleoplasmHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleolusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
chromosomeHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
nucleusHistone-lysine N-methyltransferase SETD7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (381)

Assay IDTitleYearJournalArticle
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1517774Cytotoxicity against human LS174T cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1412792Selectivity ratio of IC50 for recombinant human N-terminal His-tagged PKM1 expressed in Escherichia coli to IC50 for recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli2018MedChemComm, Apr-01, Volume: 9, Issue:4
Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor
AID1882711Anticancer activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1491470Antiproliferative activity against human NCI-H1299 cells after 48 hrs by MTS assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1402721Cell cycle arrest in human HeLa cells assessed as accumulation of cells at S phase at 1 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 20.45%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID490425Cytotoxicity against human K562 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1736454Antiproliferative activity against drug resistant human K562 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1877712Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 4 uM after 24 hrs by flow cytometry (Rvb = 1.22%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID338690Antimicrobial activity against Candida utilis IFO 0454 at 200 ug/mL after 7 days by paper disk method
AID1882695Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882760Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1524652Inhibition of topoisomerase 2 in human HeLa cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1348118Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
AID1882764Antiproliferative activity against human MG-63 cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1348116Cytotoxicity against human HCT15 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
AID1882770Cytotoxicity against African green monkey Vero cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID367215Cytotoxicity agaisnt human HeLa cells by SRB assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological activity of novel shikonin analogues.
AID357213Ratio of MBC to MIC for Staphylococcus aureus2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID547647Toxicity in mouse S180 cells xenografted Kunming mouse assessed as hypotrichosis at 4 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1402723Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G1 phase at 2 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 64.58%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID644398Reversible inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate compound pre-incubated prior to substrate addition by fluori2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID644396Noncompetitive inhibition of recombinant influenza A virus H1N1 A/Bervig_Mission/1/18 sialidase activity using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by Lineweaver-Burk and Dixon plot analysis2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1517765Inhibition of recombinant Cdc25B (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID332845Decrease in histamine-induced capillary permeability in Wistar rat assessed as inhibition of pontamine sky blue 6BX dye leakage at 50 ug treated topically relative to control
AID357216Ratio of MBC to MIC for vancomycin-resistant Enterococcus faecium F935 expressing VanA2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID357215Ratio of MBC to MIC for Enterococcus faecalis2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1877682Antiproliferative activity against human MDA-MB-231 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882701Inhibition of bovine brain tubulin polymerization preincubated with compound followed by GTP addition and measured after 20 mins by turbidimetry-based spectrophotometric method2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1577683Cytotoxicity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID1736445Antiproliferative activity against human HCT116 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID644395Inhibition of recombinant influenza A virus H1N1 A/Bervig_Mission/1/18 sialidase activity using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by fluorimetric analysis2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1736446Antiproliferative activity against human MDA-MB-231 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1736514Induction of apoptosis in human HT-29 cells assessed as viable cells at 0.25 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1610894Antiproliferative activity against human H460 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1882736Antiproliferative activity against human MDA-MB-436 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID356963Antibacterial activity against Enterococcus faecalis after 48 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1188017Cytotoxicity against human K562 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
AID338684Antimicrobial activity against Pseudomonas aeruginosa IFO 12689 at 200 ug/mL after 24 hrs by paper disk method
AID363329Cytotoxicity against MDR1 Pgp overexpressing human HepG2 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID748719Antitumor activity against lung cancer cells in lung cancer patient assessed as remission rate relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Therapeutic agents triggering nonapoptotic cancer cell death.
AID1348120Cytotoxicity against human HSF cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
AID1517790Inhibition of recombinant HNE (unknown origin) at <50 uM using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methylcoumarin, as a substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1808019Inhibition of SARS CoV2 C-terminal His6-tagged 3CL protease (3264 to 3569 residues) expressed in Escherichia coli BL21 DE3 using rr-K(MCA)-ATLQAIAS-K(DNP)-COOH preincubated for 1 hr followed by substrate addition and measured after 1 hr in presence of 0.02021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID547639Cytotoxicity against human MCF7 cells after 24 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID220230Inhibitory activity against Saccharomyces cerevisiae Tyrosine phosphatase 12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1736452Selectivity index, ratio of IC50 for drug resistant human MCF7 cells to IC50 for human MCF7 cells2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882763Cytotoxicity against human MCF-10A cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1494883Inhibition of Staphylococcus aureus SrtA deltaN24 mutant assessed as decrease in transpeptidation of IsdA (64 to 323 residues) incubated for 1.25 hrs in presence of NH2-Gly3 nucleophile by SDS-PAGE method2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Quinone skeleton as a new class of irreversible inhibitors against Staphylococcus aureus sortase A.
AID338689Antimicrobial activity against Candida tropicalis IFO 0006 at 200 ug/mL after 7 days by paper disk method
AID332846Decrease in histamine-induced capillary permeability in Wistar rat assessed as inhibition of pontamine sky blue 6BX dye leakage at 100 ug treated topically relative to control
AID1610893Antiproliferative activity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID685501HARVARD: Inhibition of liver stage Plasmodium berghei infection in HepG2 cells2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID356967Antibacterial activity against vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB after 48 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1881865Inhibition of human N-terminal His tagged PKM2 expressed in Escherichia coli Gly128, Ser205, Lys367, Gly208, Ile335, Gly363, Asn75, Ser362, lle51 residues2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1882700Anticancer activity against human DU-145 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882758Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID332848Antiinflammatory activity against thermal injury-induced edema in Wistar rat skin assessed as inhibition of edema at 100 ug treated topically relative to control
AID644403Inhibition of rhamnosidase at 200 uM2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1882732Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1402776Antitumor activity against human HeLa cells xenografted in nude mouse assessed as reduction in tumor size at 1 mg/kg, ip administered once in every 2 days for 15 days relative to control2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1412790Inhibition of recombinant human N-terminal His-tagged PKM1 expressed in Escherichia coli preincubated for 25 mins in presence of PEP/FBP followed by ADP/NADH addition measured after 25 mins by PK-LDH assay2018MedChemComm, Apr-01, Volume: 9, Issue:4
Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor
AID1882728Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1877688Antiproliferative activity against human H1650 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1402725Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 2 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 14.97%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID357214Ratio of MBC to MIC for methicillin-resistant Staphylococcus aureus 8-8S2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID357217Ratio of MBC to MIC for vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1736525Induction of apoptosis in human HT-29 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1494881Growth inhibition of Staphylococcus aureus Newman at 50 uM measured every hour2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Quinone skeleton as a new class of irreversible inhibitors against Staphylococcus aureus sortase A.
AID338699Antimicrobial activity against Microsporum gypseum IFO 8307 after 7 days by agar dilution streak method
AID1297980Cytotoxicity against human MIAPaCa2 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.
AID1736471Cell cycle arrest in human HT29 cells assessed as cell accumulation at S phase at 0.25 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 17.15 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882703Anticancer activity against human A875 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882710Anticancer activity against human HepG2 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID56871Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells1995Journal of medicinal chemistry, Mar-17, Volume: 38, Issue:6
Acylshikonin analogues: synthesis and inhibition of DNA topoisomerase-I.
AID748718Antitumor activity against lung cancer cells in lung cancer patient assessed as survival rate relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Therapeutic agents triggering nonapoptotic cancer cell death.
AID1692494Inhibition of SARS-CoV2 3C-like protease expressed in Escherichia coli BL21 (DE3) cells using Mca-AVLQSGFR-K(Dnp)K as substrate by fluorescence method2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
COVID-19: Drug Targets and Potential Treatments.
AID1736477Cell cycle arrest in human HT29 cells assessed as cell accumulation at S phase at 1 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 17.15 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1491466Inhibition of recombinant human N-terminal His-tagged PKL expressed in Escherichia coli preincubated for 15 mins followed by PEP/NADH addition measured at 30 secs interval for 3 to 6 mins by fluorescent PK-LDH assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1610895Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1882731Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID644394Competitive inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by Lineweaver-Burk and Dixon plot analysis2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1882713Antitubulin activity against bovine brain tubulin polymerization preincubated with compound followed by GTP addition by turbidimetry-based spectrophotometric method2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882772Anticancer activity against human MCF7 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882777Anticancer activity against human MGC-803 cells incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID332847Antiinflammatory activity against thermal injury-induced edema in Wistar rat skin assessed as inhibition of edema at 50 ug treated topically relative to control
AID1402724Cell cycle arrest in human HeLa cells assessed as accumulation of cells at S phase at 2 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 20.45%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1877695Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 8 uM measured after 24 hrs by flow cytometry (Rvb = 73.33%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882735Antiproliferative activity against human BT-474 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID356959Antibacterial activity against Staphylococcus aureus after 48 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID685500HARVARD: Cytotoxicity in HepG2 cell line2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1882696Cytotoxicity against human Ca9-22 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID99424Inhibition of human Leukocyte Antigen Related(LAR) protein tyrosine phosphatase D12004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1736470Cell cycle arrest in human HT29 cells assessed as cell accumulation at G2 phase at 0.25 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12.53 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1491465Selectivity ratio of IC50 for recombinant human N-terminal His-tagged PKM1 expressed in Escherichia coli BL21 to IC50 for recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli BL212017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1491464Inhibition of recombinant human N-terminal His-tagged PKM1 expressed in Escherichia coli BL21 preincubated for 15 mins followed by PEP/NADH addition measured at 30 secs interval for 3 to 6 mins by fluorescent PK-LDH assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1736444Antiproliferative activity against human HT29 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1610891Antiproliferative activity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID338692Antimicrobial activity against Micrococcus roseus IFO 3764 after 24 hrs by agar dilution streak method
AID1877686Antiproliferative activity against human Calu-3 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882775Anticancer activity against human HCT-15 cells incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882725Antiproliferative activity against human SCC-4 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877714Induction of apoptosis in human A549 cells assessed as necrotic cells at 4 uM after 24 hrs by flow cytometry (Rvb = 0.955%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1491473Selectivity index, ratio of IC50 for human BEAS2B cells to IC50 for human NCI-H1299 cells2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1882729Antiproliferative activity against human MDA-MB-468 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID644401Inhibition of alpha-glucosidase at 200 uM2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID305641Inhibition of human ACAT1 expressed in Hi5 cells2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
AID1736515Induction of apoptosis in human HT-29 cells assessed as early apoptotic cells at 0.25 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.1 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1402722Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 1 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 14.97%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID338683Antimicrobial activity against Escherichia coli NIHJ IFO 12734 at 200 ug/mL after 24 hrs by paper disk method
AID1882737Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1517763Inhibition of recombinant Cdc25A (unknown origin) using OMFP as substrate measured every 30 sec for 10 mins by fluorometric assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1610892Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1402705Antiproliferative activity against human MDA231 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1736450Antiproliferative activity against human MCF7 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID608267Antitumor activity against human CNE cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
AID338696Antimicrobial activity against Trichophyton rubrum IFO 5808 after 7 days by agar dilution streak method
AID367224Reduction of hypoxia-induced HIF1alpha accumulation in human MDA-MB-231 cells at 10 uM by Western blotting analysis2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological activity of novel shikonin analogues.
AID1877687Antiproliferative activity against human H460 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID547652Toxicity in mouse S180 cells xenografted Kunming mouse assessed as mortality at 4 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID490428Cytotoxicity against human HL60 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1638216Cytotoxicity against human K562 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
AID1420551Antiangiogenic activity in HUVEC assessed as inhibition of tube formation at 1.6 uM after 24 hrs by light microscopic analysis relative to control2018Bioorganic & medicinal chemistry letters, 10-15, Volume: 28, Issue:19
Eupatilin inhibits angiogenesis-mediated human hepatocellular metastasis by reducing MMP-2 and VEGF signaling.
AID1736449Antiproliferative activity against human LO2 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID490426Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1882724Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877684Antiproliferative activity against human A549 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1524657Cytotoxicity against human L02 cells assessed as inhibition of cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1736521Induction of apoptosis in human HT-29 cells assessed as necrotic cells at 0.5 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID547638Cytotoxicity against human HT-29 cells after 24 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1736517Induction of apoptosis in human HT-29 cells assessed as necrotic cells at 0.25 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882766Antiproliferative activity against mouse B16-F10 cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID357212Antibacterial activity against Pseudomonas aeruginosa up to 100 ug/mL after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1736518Induction of apoptosis in human HT-29 cells assessed as viable cells at 0.5 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1808020Inhibition of porcine heart malate dehydrogenase preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1736451Antiproliferative activity against drug-resistant human MCF7 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID356964Antibacterial activity against vancomycin-resistant Enterococcus faecium F935 expressing VanA after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID8453The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Shikonin derivatives: synthesis and inhibition of human telomerase.
AID1882741Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID1877696Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 8 uM measured after 24 hrs by flow cytometry (Rvb = 15.37%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1517768Cytotoxicity against human MONO-MAC-6 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1368255Inhibition of recombinant human N-terminal His6/SUMO-tagged PKM2 expressed in Escherichia coli BL21 using PEP as substrate incubated for 30 mins in presence of ADP by spectrophotometric based LDH enzyme coupled assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2.
AID547645Antitumor activity against mouse S180 cells xenografted in Kunming mouse assessed as inhibition of tumor growth at 1 mg/kg/day, ip for 9 days relative to control2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID374458Cytotoxicity against human Bel7402 cells by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antitumor activity of 6- and 2-(1-substituted-thio-4-methylpent-3-enyl)-5,8-dimethoxynaphthalene-1,4-diones.
AID1736472Cell cycle arrest in human HT29 cells assessed as cell accumulation at G1 phase at 0.5 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 70.33 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID367216Cytotoxicity against human HL60 cells by MTT assay2009Bioorganic & medicinal chemistry letters, Feb-01, Volume: 19, Issue:3
Synthesis and biological activity of novel shikonin analogues.
AID1882774Cytotoxicity against human skin fibroblast cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882739Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1412804Selectivity ratio of IC50 for recombinant human N-terminal His-tagged PKL expressed in Escherichia coli to IC50 for recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli2018MedChemComm, Apr-01, Volume: 9, Issue:4
Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor
AID748720Antitumor activity against lung cancer cells in lung cancer patient assessed as tumor growth inhibition relative to control2013Journal of medicinal chemistry, Jun-27, Volume: 56, Issue:12
Therapeutic agents triggering nonapoptotic cancer cell death.
AID1882718Antiproliferative activity against human BGC cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1402707Antiproliferative activity against human A549 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID608268Antitumor activity against human MDA-MB-231 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
AID1882740Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1736522Induction of apoptosis in human HT-29 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 97.7 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1877723Induction of apoptosis in human A549 cells assessed as live cells at 4 uM after 36 hrs by flow cytometry (Rvb = 92.5%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1808026Inhibition of SARS-CoV2 main protease expressed in Escherichia coli using Mca-AVLQSGFRK(Dnp)K as substrate by fluorescence assay2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID547641Cytotoxicity against human HSF after 24 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1517772Cytotoxicity against human U937 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1882722Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882730Cytotoxicity against human MCF-10A assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID608269Cytotoxicity against mouse L929 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
AID1832330Cytotoxicity against HFF-1 cells assessed as cell growth inhibition measured after 24 hrs by MTT assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Discovery of juglone and its derivatives as potent SARS-CoV-2 main proteinase inhibitors.
AID338691Antimicrobial activity against Staphylococcus aureus 209P IFO 12732 after 24 hrs by agar dilution streak method
AID1610890Cytotoxicity against human LO2 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1524656Inhibition of topoisomerase 2 in human MDA-MB-231 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1524655Inhibition of topoisomerase 2 in human MCF7 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1348119Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
AID1736474Cell cycle arrest in human HT29 cells assessed as cell accumulation at S phase at 0.5 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 17.15 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID338688Antimicrobial activity against Candida mycoderma IFO 0162 at 200 ug/mL after 7 days by paper disk method
AID1882714Antitubulin activity against bovine brain tubulin polymerization preincubated with compound followed by GTP addition and measured after 20 mins by turbidimetry-based spectrophotometric method2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1845234Inhibition of SARS-CoV-2 MPro expressed in Escherichia coli BL21 (DE3) using Mca-AVLQ SGFR-K(Dnp)K as substrate by EnVision multimode plate reader analysis2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID1736524Induction of apoptosis in human HT-29 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.5 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID644402Inhibition of beta-glucosidase at 200 uM2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1491468Antiproliferative activity against human HCT116 cells after 48 hrs by MTS assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1882726Cytotoxicity against African green monkey VERO cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877711Induction of apoptosis in human A549 cells assessed as live cells at 4 uM after 24 hrs by flow cytometry (Rvb = 92%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1577681Cytotoxicity against HEK293T cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID1882773Anticancer activity against human K562 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1610973Toxicity in ip dosed Balb/c mouse xenografted with human A549 cells assessed as reduction in body weight at 2 mg/kg, ip administered once every two days for 32 days and measured for every 2 days2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1882715Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID338700Antimicrobial activity against Epidermophyton floccosum IFO 9045 after 7 days by agar dilution streak method
AID547646Antitumor activity against mouse S180 cells xenografted in Kunming mouse assessed as inhibition of tumor growth at 25 mg/kg/day, ip for 9 days relative to control2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1877704Cell cycle arrest in human A549 cells assessed as accumulation at G1 phase at 4 uM measured after 36 hrs by flow cytometry (Rvb = 77.38%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1517787Binding affinity to MKK7 (unknown origin) expressed in HEK293 cells assessed as dissociation constant at <30 uM by kinomescan method2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1297981Cytotoxicity against human MCF7 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.
AID490424Cytotoxicity against human K562/ADR cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1577682Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID1882720Antiproliferative activity against human L02 cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877685Cytotoxicity against human L02 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID547655Toxicity in mouse S180 cells xenografted Kunming mouse assessed as mortality at 1.5 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID338694Antimicrobial activity against Bacillus subtilis PCI 219 IFO 3513 after 24 hrs by agar dilution streak method
AID547654Toxicity in mouse S180 cells xenografted Kunming mouse assessed as bloody ascites at 4 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID157217Inhibition of human PTPase 1B2004Bioorganic & medicinal chemistry letters, Apr-19, Volume: 14, Issue:8
Evans Blue and other dyes as protein tyrosine phosphatase inhibitors.
AID1736448Antiproliferative activity against human HEK293T cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882768Antiproliferative activity against human MDA-MB-231 cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1638218Selectivity index, ratio of IC50 for human HSF cells to IC50 for human HCT15 cells2019European journal of medicinal chemistry, Mar-01, Volume: 165Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
AID1882697Anticancer activity against mouse B16-F10 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1845236Inhibition of SARS-CoV-2 MPro2021Bioorganic & medicinal chemistry, 01-01, Volume: 29Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
AID1297982Cytotoxicity against human MCF10 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.
AID1882709Anticancer activity against human A875 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID490431Resistant factor, ratio of IC50 for human MCF7/ADR cells to IC50 for human MCF7 cells2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1882727Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1524653Inhibition of topoisomerase 2 in human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1736453Antiproliferative activity against human K562 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1402726Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G1 phase at 4 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 64.58%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID338686Antimicrobial activity against Candida albicans IFO 0197 at 200 ug/mL after 7 days by paper disk method
AID1882765Antiproliferative activity against human MCF7 cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID356962Antibacterial activity against Enterococcus faecalis after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1877726Induction of apoptosis in human A549 cells assessed as necrotic cells at 4 uM after 36 hrs by flow cytometry (Rvb = 0.379%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID356968Antibacterial activity against Escherichia coli up to 100 ug/mL after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1877725Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 4 uM after 36 hrs by flow cytometry (Rvb = 5.84%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882761Antiproliferative activity against human HCT-8 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID685503HARVARD: Inhibition of blood stage Plasmodium falciparum Dd2 infection2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1736523Induction of apoptosis in human HT-29 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.1 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1517775Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1882704Anticancer activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1667214Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 25 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1348117Cytotoxicity against human MGC803 cells after 48 hrs by MTT assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Synthesis and biological evaluation of sulfur-containing shikonin oxime derivatives as potential antineoplastic agents.
AID1524654Inhibition of topoisomerase 2 in human CNE1 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1577679Cytotoxicity against human L02 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID1491469Antiproliferative activity against human HeLa cells after 48 hrs by MTS assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1882719Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID305644Selectivity for human ACAT1 over human ACAT22007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
AID1610897Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells after 30 mins in presence of gamma-[32p-ATP] binding assay2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID490430Resistant factor, ratio of IC50 for human K562/ADR cells to IC50 for human K562 cells2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID644393Inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate by fluorimetric analysis2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1736469Cell cycle arrest in human HT29 cells assessed as cell accumulation at G1 phase at 0.25 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 70.33 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1494880Inhibition of Staphylococcus aureus SrtA deltaN24 mutant transpeptidation activity using abz-LPATG-dnp as substrate preincubated for 10 mins followed by substrate addition measured every 2 mins for 20 mins by FRET assay2018Bioorganic & medicinal chemistry letters, 06-01, Volume: 28, Issue:10
Quinone skeleton as a new class of irreversible inhibitors against Staphylococcus aureus sortase A.
AID1517769Cytotoxicity against human HL60 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID356958Antibacterial activity against Staphylococcus aureus after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID547642Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1877683Antiproliferative activity against human MCF7 cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1577646Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID1877697Cell cycle arrest in human A549 cells assessed as accumulation at G2 phase at 8 uM measured after 24 hrs by flow cytometry (Rvb = 11.3%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882759Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID356961Antibacterial activity against methicillin-resistant Staphylococcus aureus 8-8S after 48 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1882698Anticancer activity against human MG-63 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID81147The compound was tested in vitro for its cytotoxicity against human HL-60 cancer cell line by MTT method at 1 uM concentration; Slight inhibition2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Shikonin derivatives: synthesis and inhibition of human telomerase.
AID1882712Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882717Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1808021Inhibition of porcine heart malate dehydrogenase assessed as reduction in enzyme inhibition at 3 times IC50 preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec in presence of 0.01% Triton-X100 by spectrop2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1736520Induction of apoptosis in human HT-29 cells assessed as late apoptotic cells at 0.5 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.5 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1402708Antiproliferative activity against human LO2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1667213Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 50 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1638215Cytotoxicity against human MGC803 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
AID1517776Cytotoxicity against human PBMC cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1638214Cytotoxicity against human HCT15 cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
AID1517767Cytotoxicity against human THP1 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID356965Antibacterial activity against vancomycin-resistant Enterococcus faecium F935 expressing VanA after 48 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID490429Cytotoxicity against human HL60/ADR cells after 72 hrs by MTT assay2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1882721Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1736473Cell cycle arrest in human HT29 cells assessed as cell accumulation at G2 phase at 0.5 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12.53 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1877705Cell cycle arrest in human A549 cells assessed as accumulation at S phase at 4 uM measured after 36 hrs by flow cytometry (Rvb = 12.6%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID547653Toxicity in mouse S180 cells xenografted Kunming mouse assessed as reduction of body weight at 4 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID305640Inhibition of human ACAT2 expressed in Hi5 cells2007Bioorganic & medicinal chemistry letters, Feb-15, Volume: 17, Issue:4
Human ACAT inhibitory effects of shikonin derivatives from Lithospermum erythrorhizon.
AID1882738Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID374460Cytotoxicity against human SPC-A1 cells by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antitumor activity of 6- and 2-(1-substituted-thio-4-methylpent-3-enyl)-5,8-dimethoxynaphthalene-1,4-diones.
AID1188016Cytotoxicity against human MCF7 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
AID338698Antimicrobial activity against Trichophyton tonsurans var. sulfureum IFO 5945 after 7 days by agar dilution streak method
AID1083211Bactericidal activity against Erwinia amylovora 295/93 assessed as growth inhibition in King's B full medium measured at pH 7.2 after overnight incubation by suspension culture assay2012Journal of agricultural and food chemistry, Dec-12, Volume: 60, Issue:49
Potent and specific bactericidal effect of juglone (5-hydroxy-1,4-naphthoquinone) on the fire blight pathogen Erwinia amylovora.
AID547649Toxicity in mouse S180 cells xenografted Kunming mouse assessed as change body weight at 1 mg/kg/day, ip for 9 days (Rvb = 57.8%)2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1736519Induction of apoptosis in human HT-29 cells assessed as early apoptotic cells at 0.5 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 1.1 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1877681Antiproliferative activity against human HeLa cells by CCK8 assay2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1882733Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882716Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 20 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1736447Antiproliferative activity against human A549 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1412803Inhibition of recombinant human N-terminal His-tagged PKL expressed in Escherichia coli preincubated for 25 mins in presence of PEP/FBP followed by ADP/NADH addition measured after 25 mins by PK-LDH assay2018MedChemComm, Apr-01, Volume: 9, Issue:4
Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor
AID1402778Toxicity in nude mouse xenografted with human HeLa cells assessed as loss in body weight at 1 mg/kg, ip administered once in every 2 days for 15 days2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1882734Cytotoxicity against human HEK293T cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1667216Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to control2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1667215Inhibition of human SET7 overexpressed in Escherichia coli BL21 (DE3) cells at 12.5 uM preincubated for 15 mins followed by addition of SAM as substrate and biotinylated Histone H3 (1-50) peptide measured after 30 mins by AlphaLISA assay relative to contr2020Bioorganic & medicinal chemistry, 04-01, Volume: 28, Issue:7
Computational discovery and biological evaluation of novel inhibitors targeting histone-lysine N-methyltransferase SET7.
AID1736476Cell cycle arrest in human HT29 cells assessed as cell accumulation at G2 phase at 1 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 12.53 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1402727Cell cycle arrest in human HeLa cells assessed as accumulation of cells at S phase at 4 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 20.45%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID490432Resistant factor, ratio of IC50 for human HL60/ADR cells to IC50 for human HL60 cells2010European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
Synthesis and antitumor activity of new shikonin glycosides.
AID1491463Inhibition of recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli BL21 preincubated for 15 mins followed by PEP/NADH addition measured at 30 secs interval for 3 to 6 mins by fluorescent PK-LDH assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1491472Cytotoxicity against human BEAS2B cells assessed as reduction in cell viability after 48 hrs by MTS assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID1882706Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877724Induction of apoptosis in human A549 cells assessed as early apoptotic cells at 4 uM after 36 hrs by flow cytometry (Rvb = 1.24%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID338685Antimicrobial activity against Serratia marcescens IFO 12648 at 200 ug/mL after 24 hrs by paper disk method
AID547640Cytotoxicity against human K562 cells after 24 hrs by MTT assay2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1610896Inhibition of C-terminal His-tagged N-terminal GST-tagged human EGFR (668 to 1210 residues) expressed in baculovirus infected Sf9 cells at 150 nM after 30 mins in presence of gamma-[32p-ATP] binding assay relative to control2019Bioorganic & medicinal chemistry, 12-01, Volume: 27, Issue:23
Design, synthesis and biological evaluation of benzoylacrylic acid shikonin ester derivatives as irreversible dual inhibitors of tubulin and EGFR.
AID1736455Selectivity index, ratio of IC50 for drug resistant human K562 cells to IC50 for human K562 cells2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID646469Binding affinity to human telomeric G-quadruplex DNA at 200 uM after 1 hr by ESI-TOF-MS analysis2012Bioorganic & medicinal chemistry letters, Feb-15, Volume: 22, Issue:4
Synthesis and human telomeric G-quadruplex DNA-binding activity of glucosaminosides of shikonin/alkannin.
AID336961Displacement of [3H]TPA from TPA receptor in ICR mouse dorsal epidermis
AID1882707Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1188018Cytotoxicity against human skin fibroblast cells by MTT assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
AID1402706Antiproliferative activity against human HeLa cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1882762Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 24 hrs by CCK-8 assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID363328Cytotoxicity against MDR1 Pgp under-expressing human HCT116 cells after 24 hrs by MTT assay2008European journal of medicinal chemistry, Jun, Volume: 43, Issue:6
Comparison of the cytotoxic activities of naturally occurring hydroxyanthraquinones and hydroxynaphthoquinones.
AID1808022Inhibition of porcine heart malate dehydrogenase assessed as critical aggregation concentration preincubated for 5 min followed by nicotinamide adenine dinucleotide addition and monitered for 90 sec by spectrophotometric method2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Colloidal Aggregators in Biochemical SARS-CoV-2 Repurposing Screens.
AID1736516Induction of apoptosis in human HT-29 cells assessed as late apoptotic cells at 0.25 uM measured after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.5 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID338687Antimicrobial activity against Candida guilliermondii IFO 0454 at 200 ug/mL after 7 days by paper disk method
AID1736443Antiproliferative activity against human HepG2 cells incubated for 48 hrs by MTT assay2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID1882771Cytotoxicity against human MCF-10A incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID356960Antibacterial activity against methicillin-resistant Staphylococcus aureus 8-8S after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1736475Cell cycle arrest in human HT29 cells assessed as cell accumulation at G1 phase at 1 uM incubated for 24 hrs by propidium iodide staining based flow cytometry (Rvb = 70.33 %)2020European journal of medicinal chemistry, Mar-15, Volume: 190Synthesis and biological evaluation of novel shikonin-benzo[b]furan derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID547656Toxicity in mouse S180 cells xenografted Kunming mouse assessed as adverse effects at 1.5 mg/kg/day, ip for 4 days2010European journal of medicinal chemistry, Dec, Volume: 45, Issue:12
Semi-synthesis and anti-tumor activity of 5,8-O-dimethyl acylshikonin derivatives.
AID1882708Cytotoxicity against human L02 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1517773Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1188015Cytotoxicity against human DU145 cells by MTT assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Synthesis and evaluation of novel alkannin and shikonin oxime derivatives as potent antitumor agents.
AID1402720Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G1 phase at 1 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 64.58%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID152352The compound was tested in vitro for its cytotoxicity against human P-388 cancer cell line by MTT method at 1 uM concentration; Slight inhibition2002Bioorganic & medicinal chemistry letters, May-20, Volume: 12, Issue:10
Shikonin derivatives: synthesis and inhibition of human telomerase.
AID338693Antimicrobial activity against Micrococcus luteus IFO 12708 after 24 hrs by agar dilution streak method
AID1882723Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1297978Cytotoxicity against human HeLa cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.
AID685502HARVARD: Inhibition of blood stage Plasmodium falciparum 3D7 infection2012Proceedings of the National Academy of Sciences of the United States of America, May-29, Volume: 109, Issue:22
Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
AID1491467Selectivity ratio of IC50 for recombinant human N-terminal His-tagged PKL expressed in Escherichia coli to IC50 for recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli BL212017European journal of medicinal chemistry, Sep-29, Volume: 138Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
AID608266Antitumor activity against human HCT15 cells after 24 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Semi-synthesis and antitumor activity of 6-isomers of 5, 8-O-dimethyl acylshikonin derivatives.
AID1882769Cytotoxicity against human L02 incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1524651Inhibition of topoisomerase 2 in human HepG2 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Design, synthesis and biological evaluation of 1,4-dihydroxyanthraquinone derivatives as anticancer agents.
AID1882767Antiproliferative activity against human HepG2 cells incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1402731Inhibition of microtubule polymerization in human HeLa cells at 4 uM after 24 hrs by rhodamine/DAPI staining-based confocal microscopic analysis2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID338695Antimicrobial activity against Saccharomyces sake IFO 0305 after 7 days by agar dilution streak method
AID644397Inhibition of Clostridium perfringens ATCC 10543 sialidase Nan1 c-terminal catalytic domain using 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid sodium salt hydrate as substrate at IC50 concentration pre-incubated for 10 mins prior substrate additio2012Bioorganic & medicinal chemistry, Mar-01, Volume: 20, Issue:5
Selective and slow-binding inhibition of shikonin derivatives isolated from Lithospermum erythrorhizon on glycosyl hydrolase 33 and 34 sialidases.
AID1877706Cell cycle arrest in human A549 cells assessed as accumulation at G2 phase at 4 uM measured after 36 hrs by flow cytometry (Rvb = 10.02%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID374459Cytotoxicity against human HT-29 cells by MTT assay2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Synthesis and antitumor activity of 6- and 2-(1-substituted-thio-4-methylpent-3-enyl)-5,8-dimethoxynaphthalene-1,4-diones.
AID1368256Selectivity ratio of IC50 for recombinant human N-terminal His6/SUMO-tagged PKM1 expressed in Escherichia coli BL21 to IC50 for recombinant human N-terminal His6/SUMO-tagged PKM2 expressed in Escherichia coli BL212017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2.
AID1882702Anticancer activity against human SW872 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1402704Antiproliferative activity against human HepG2 cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1882705Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1877713Induction of apoptosis in human A549 cells assessed as late apoptotic cells at 4 uM after 24 hrs by flow cytometry (Rvb = 5.85%)2022Bioorganic & medicinal chemistry letters, 02-01, Volume: 57Shikonin N-benzyl matrinic acid ester derivatives as novel telomerase inhibitors with potent activity against lung cancer cell lines.
AID1402709Antiproliferative activity against human 293T cells after 24 hrs by MTT assay2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1368254Inhibition of recombinant human N-terminal His6/SUMO-tagged PKM1 expressed in Escherichia coli BL21 using PEP as substrate incubated for 30 mins in presence of ADP by spectrophotometric based LDH enzyme coupled assay2017Bioorganic & medicinal chemistry letters, 12-15, Volume: 27, Issue:24
Scutellarin inhibits Hela cell growth and glycolysis by inhibiting the activity of pyruvate kinase M2.
AID1517770Cytotoxicity against human SW982 cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1882778Cytotoxicity against human skin fibroblast cells incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1297979Cytotoxicity against human MDA-MB-231 cells assessed as reduction in cell growth after 72 hrs by cell titer glo assay2016Bioorganic & medicinal chemistry letters, 06-01, Volume: 26, Issue:11
One-pot synthesis of 1,4-dihydroxy-2-((E)-1-hydroxy-4-phenylbut-3-enyl)anthracene-9,10-diones as novel shikonin analogs and evaluation of their antiproliferative activities.
AID1882776Anticancer activity against human MCF7 cells incubated for 72 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1882699Anticancer activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID1881860Inhibition of PKM2 (unknown origin)2022Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
A Perspective on Medicinal Chemistry Approaches for Targeting Pyruvate Kinase M2.
AID1402728Cell cycle arrest in human HeLa cells assessed as accumulation of cells at G2/M phase at 4 uM after 24 hrs by propidium iodide staining-based FACScan flow cytometric analysis (Rvb = 14.97%)2018European journal of medicinal chemistry, Jan-20, Volume: 144Design and characterization of α-lipoic acyl shikonin ester twin drugs as tubulin and PDK1 dual inhibitors.
AID1517771Cytotoxicity against human Jurkat cells assessed as reduction in cell viability incubated for 24 hrs by CellTiter-Glo luminescent cell viability assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Synthesis, anticancer activity, and molecular modeling of 1,4-naphthoquinones that inhibit MKK7 and Cdc25.
AID1412789Inhibition of recombinant human N-terminal His-tagged PKM2 expressed in Escherichia coli preincubated for 25 mins in presence of PEP/FBP followed by ADP/NADH addition measured after 25 mins by PK-LDH assay2018MedChemComm, Apr-01, Volume: 9, Issue:4
Anti-cancer effect of a novel 2,3-didithiocarbamate-substituted naphthoquinone as a tumor metabolic suppressor
AID1882812Antiproliferative activity against human SK-BR-3 cells assessed as inhibition of cell growth incubated for 24 hrs in presence of foetal bovine serum by MTT assay2022European journal of medicinal chemistry, May-05, Volume: 235Recent advances of antitumor shikonin/alkannin derivatives: A comprehensive overview focusing on structural classification, synthetic approaches, and mechanisms of action.
AID356966Antibacterial activity against vancomycin-resistant Enterococcus faecalis CKU-17 expressing VanB after 24 hrs by broth microdilution method2002Journal of natural products, Dec, Volume: 65, Issue:12
Antimicrobial activities of naphthazarins from Arnebia euchroma.
AID1577656Cytotoxicity against human A549 cells assessed as reduction in cell viability after 24 hrs by MTT assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Coumarin-containing hybrids and their anticancer activities.
AID338697Antimicrobial activity against Trichophyton mentagrophytes IFO 5809 after 7 days by agar dilution streak method
AID1638217Cytotoxicity against human HSF cells after 72 hrs by MTT assay2019European journal of medicinal chemistry, Mar-01, Volume: 165Discovery and synthesis of sulfur-containing 6-substituted 5,8-dimethoxy-1,4-naphthoquinone oxime derivatives as new and potential anti-MDR cancer agents.
AID228426Inhibition of topoisomerase I1998Bioorganic & medicinal chemistry letters, Dec-01, Volume: 8, Issue:23
Inhibition of topoisomerase I by naphthoquinone derivatives.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (647)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (0.62)18.7374
1990's30 (4.64)18.2507
2000's90 (13.91)29.6817
2010's334 (51.62)24.3611
2020's189 (29.21)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 46.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index46.43 (24.57)
Research Supply Index6.50 (2.92)
Research Growth Index5.74 (4.65)
Search Engine Demand Index72.26 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (46.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (0.30%)5.53%
Reviews29 (4.39%)6.00%
Case Studies0 (0.00%)4.05%
Observational1 (0.15%)0.25%
Other628 (95.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]